Seres Therapeutics' ECOSPOR III Study Data on SER-109 Published in Journal of the American Medical Association
yahoo.com
news
2022-10-19 18:00:00

– Summarized data from the study's secondary endpoints show investigational oral microbiome therapeutic rapidly and durably lowered risk of recurrent C. difficile infection –

CAMBRIDGE, Mass., October 19, 2022--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced the publication of Phase 3 clinical data in the Journal of the American Medical Association (JAMA), highlighting that the clinical benefits of investigational therapeutic SER-109 for preventing recurrent C.
